A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.11.05.20226373: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Ethical approval was obtained from the Institutional Review Board of the participating site. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Outcome Measures: Data on clinical and laboratory findings, including mortality, length of hospital stay (LOHS), and safety outcomes (adverse events [AEs], serious adverse events [SAEs], and suspected drug-related hypersensitivity reactions) were extracted from the medical records. SAEs]suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers …
SciScore for 10.1101/2020.11.05.20226373: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Ethical approval was obtained from the Institutional Review Board of the participating site. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Outcome Measures: Data on clinical and laboratory findings, including mortality, length of hospital stay (LOHS), and safety outcomes (adverse events [AEs], serious adverse events [SAEs], and suspected drug-related hypersensitivity reactions) were extracted from the medical records. SAEs]suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has some limitations, such as the retrospective nature of the study and the lack of a control group. However, the main outcome measure here is the impact of SORT interval ≤9 days and >9 days, when all patients received remdesivir. On a real-world practice front, with an EUA from the FDA for remdesivir for moderate-to-severe COVID-19 at the time of the study, it was not ethically possible to do a RCT with a placebo group in this subset of sick patients. Further, our study did not evaluate the optimal duration of remdesivir treatment (5 vs 10 days), and cannot comment on the specific subset of mechanically ventilated patients, where role of the drug is controversial. Additionally, it is difficult to delineate the impact of remdesivir from other COVID-19-validated medications such as steroids, as this is one of the first studies to report uniform use of both these agents. However, the observation that mortality increased after 9 days, when steroids are known to be maximally useful, strongly suggests that the mortality benefit of SORT interval ≤9 days can be attributed to remdesivir. Additionally, we used remdesivir preparations from three different companies as the demand increased exponentially and the pharmaceutical industry geared up to handle the need.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
